Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Agenus Inc. and reminds investors of the November 5, 2024 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit against the company [1][3]. Group 1: Legal Action and Investor Information - Investors who suffered losses exceeding $50,000 in Agenus between January 23, 2023, and July 17, 2024, are encouraged to contact Faruqi & Faruqi to discuss their legal rights [1]. - The complaint alleges that Agenus and its executives violated federal securities laws by making false or misleading statements regarding the effectiveness of their combination therapy, botensilimab and balstilimab [3][4]. - The court-appointed lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [5]. Group 2: Company Performance and Stock Impact - On July 18, 2024, Agenus announced that the FDA advised against the submission of clinical results for accelerated approval, leading to a significant stock price drop of $10.43 per share, or 58.83%, closing at $7.30 per share [4]. - The clinical results and regulatory prospects of botensilimab and balstilimab were reportedly overstated, contributing to the misleading public statements made by the company [3].

Core Viewpoint - A class action securities lawsuit has been filed against Agenus Inc. alleging securities fraud that affected investors between January 23, 2023, and July 17, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding the effectiveness of their immuno-oncology combination therapy involving botensilimab and balstilimab, which were overstated [2]. - It is alleged that the clinical results and regulatory and commercial prospects of botensilimab and balstilimab were misrepresented, leading to materially false and misleading public statements by the Company [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 5, 2024, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [2]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [2]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [3]. - The firm has over 70 employees and extensive expertise in complex securities litigation [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Agenus Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its immuno-oncology products, botensilimab and balstilimab, during the class period from January 23, 2023, to July 17, 2024 [1]. Group 1 - The class action alleges that the combination therapy of botensilimab and balstilimab was less effective than previously claimed by the company [1]. - The complaint states that the clinical results and regulatory and commercial prospects of botensilimab and balstilimab were overstated [1]. - As a result of these allegations, the company's public statements were deemed materially false and misleading throughout the relevant period [1]. Group 2 - Shareholders who purchased shares of Agenus during the specified class period are encouraged to register for the class action, with a deadline of November 5, 2024, to seek lead plaintiff status [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3 - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Agenus Inc. securities, alleging that the company made false and misleading statements regarding its drug therapies during the specified Class Period [1][4]. Group 1: Lawsuit Details - The class action lawsuit pertains to securities purchased between January 23, 2023, and July 17, 2024, inclusive [1]. - The lawsuit claims that Agenus misrepresented the effectiveness of its combination therapy involving botensilimab and balstilimab, leading to overstated clinical results and commercial prospects [4]. - Investors are encouraged to join the class action, with the deadline to serve as lead plaintiff set for November 5, 2024 [1][2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [3]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, enhancing the firm's credibility [3].

NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Agenus Inc. (“Agenus” or the “Company”) (NASDAQ: AGEN) in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Agenus securities between January 23, 2023 and July 17, 2024, both dates inclusive (the “Class Period”). Investors have until ...

Core Viewpoint - Edelson Lechtzin LLP is investigating securities fraud claims on behalf of investors of Agenus, Inc. for the period between January 23, 2023, and July 17, 2024, due to alleged misleading statements regarding the company's business and product efficacy [1][3]. Company Overview - Agenus, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on discovering immune-oncology products. Key product candidates include balstilimab for second-line cervical cancer and botensilimab for pancreatic cancer and melanoma. The company is also exploring a combination therapy of botensilimab and balstilimab for metastatic colorectal cancer [2]. Securities Fraud Claims - The Complaint alleges that during the Class Period, Agenus's Defendants made materially false and misleading statements about the effectiveness of the combination therapy of botensilimab and balstilimab, leading to overstated clinical results and regulatory prospects [3]. Stock Price Impact - Following a statement from Agenus regarding its meeting with the FDA, which recommended against submitting results for accelerated approval due to insufficient response rates, the company's stock price dropped by $10.43 per share, or 58.83%, closing at $7.30 per share on July 18, 2024 [4].

Core Viewpoint - A class action lawsuit has been filed against Agenus Inc. for allegedly misleading investors about the effectiveness and prospects of its drug candidates, particularly botensilimab and balstilimab, during the specified class period [1][2]. Company Overview - Agenus Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology products, including balstilimab, an anti-PD-1 antagonist, and botensilimab, a CTLA-4 blocking antibody [1]. Allegations - The lawsuit claims that Agenus failed to disclose that the combination therapy of botensilimab and balstilimab was less effective than represented, leading to overstated clinical results and regulatory prospects [2]. - The company's public statements were alleged to be materially false and misleading throughout the class period [2]. Recent Developments - On July 18, 2024, Agenus announced the results of an end-of-Phase 2 meeting with the FDA, which advised against submitting results for Accelerated Approval due to concerns that objective response rates may not translate to survival benefits [3]. - Following this announcement, Agenus's stock price dropped by $10.43 per share, a decline of 58.83%, closing at $7.30 per share [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must submit their applications by November 5, 2024 [4]. - Shareholders can remain absent class members if they choose not to participate in the case [4]. Legal Representation - Robbins LLP is leading the class action and operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5]. - The firm has a history of recovering over $1 billion for shareholders since its inception in 2002 [5].

Core Viewpoint - A class action lawsuit has been filed against Agenus Inc. for alleged violations of federal securities laws, claiming that the company made materially false and misleading statements regarding its business and clinical prospects [1][2][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased Agenus securities between January 23, 2023, and July 17, 2024 [2]. - Allegations include that the combination therapy of botensilimab and balstilimab was less effective than represented, leading to overstated clinical results and regulatory prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Agenus have until November 5, 2024, to request to be appointed as lead plaintiff in the case [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - The law firm operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. - Bronstein, Gewirtz & Grossman, LLC has a history of recovering hundreds of millions of dollars for investors in securities fraud cases [6].

Core Viewpoint - A class action lawsuit has been filed against Agenus Inc. and certain officers for alleged violations of federal securities laws during the Class Period from January 23, 2023, to July 17, 2024, seeking damages for misleading statements regarding the company's business and prospects [1][5]. Company Overview - Agenus is a clinical-stage biotechnology company focused on developing immuno-oncology products, including balstilimab and botensilimab, which are in various stages of clinical trials for treating cancers such as cervical cancer, pancreatic cancer, and melanoma [3][4]. Legal Proceedings - The lawsuit, filed in the U.S. District Court for the District of Massachusetts, claims that the defendants made materially false and misleading statements about the effectiveness of their combination therapy, leading to an overstatement of clinical results and regulatory prospects [1][5]. - Shareholders who acquired Agenus securities during the Class Period have until November 5, 2024, to request appointment as Lead Plaintiff [2]. Recent Developments - On July 18, 2024, Agenus announced that the FDA advised against the submission of results for its immunotherapy combination for accelerated approval, leading to a significant stock price drop of $10.43 per share, or 58.83%, closing at $7.30 [6].

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Agenus Inc. (“Agenus” or the “Company”) (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024, inclusive (the “Class Period”). For more information, submit a form at Agenus Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, o ...